These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Effects of sEH inhibition on the eicosanoid and cytokine storms in SARS-CoV-2-infected mice. Edin ML; Gruzdev A; Graves JP; Lih FB; Morisseau C; Ward JM; Hammock BD; Bosio CM; Zeldin DC FASEB J; 2024 May; 38(10):e23692. PubMed ID: 38786655 [TBL] [Abstract][Full Text] [Related]
4. Role of arachidonic cascade in COVID-19 infection: A review. Ripon MAR; Bhowmik DR; Amin MT; Hossain MS Prostaglandins Other Lipid Mediat; 2021 Jun; 154():106539. PubMed ID: 33592322 [TBL] [Abstract][Full Text] [Related]
5. Targeting the SphK-S1P-SIPR Pathway as a Potential Therapeutic Approach for COVID-19. McGowan EM; Haddadi N; Nassif NT; Lin Y Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003377 [TBL] [Abstract][Full Text] [Related]
6. Potential usefulness of pentoxifylline, a non-specific phosphodiesterase inhibitor with anti-inflammatory, anti-thrombotic, antioxidant, and anti-fibrogenic properties, in the treatment of SARS-CoV-2. González-Pacheco H; Amezcua-Guerra LM; Sandoval J; Arias-Mendoza A Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7494-7496. PubMed ID: 32706089 [TBL] [Abstract][Full Text] [Related]
7. Pentoxifylline and Oxypurinol: Potential Drugs to Prevent the López-Iranzo FJ; López-Rodas AM; Franco L; López-Rodas G Curr Pharm Des; 2020; 26(35):4515-4521. PubMed ID: 32787748 [TBL] [Abstract][Full Text] [Related]
8. Acute inflammation and pathogenesis of SARS-CoV-2 infection: Cannabidiol as a potential anti-inflammatory treatment? Costiniuk CT; Jenabian MA Cytokine Growth Factor Rev; 2020 Jun; 53():63-65. PubMed ID: 32467020 [No Abstract] [Full Text] [Related]
9. Can Bioactive Lipids Inactivate Coronavirus (COVID-19)? Das UN Arch Med Res; 2020 Apr; 51(3):282-286. PubMed ID: 32229155 [TBL] [Abstract][Full Text] [Related]
10. Protective Effect of Epigallocatechin-3-Gallate (EGCG) in Diseases with Uncontrolled Immune Activation: Could Such a Scenario Be Helpful to Counteract COVID-19? Menegazzi M; Campagnari R; Bertoldi M; Crupi R; Di Paola R; Cuzzocrea S Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708322 [TBL] [Abstract][Full Text] [Related]
11. Is Inhaled Furosemide a Potential Therapeutic for COVID-19? Brennecke A; Villar L; Wang Z; Doyle LM; Meek A; Reed M; Barden C; Weaver DF Am J Med Sci; 2020 Sep; 360(3):216-221. PubMed ID: 32622469 [TBL] [Abstract][Full Text] [Related]
12. Cytokine storm in COVID-19 and parthenolide: Preclinical evidence. Bahrami M; Kamalinejad M; Latifi SA; Seif F; Dadmehr M Phytother Res; 2020 Oct; 34(10):2429-2430. PubMed ID: 32472655 [TBL] [Abstract][Full Text] [Related]
13. Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2. Longhitano L; Tibullo D; Giallongo C; Lazzarino G; Tartaglia N; Galimberti S; Li Volti G; Palumbo GA; Liso A Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32443911 [TBL] [Abstract][Full Text] [Related]
14. IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra). Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G; Toniato E J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1623-1627. PubMed ID: 32744052 [TBL] [Abstract][Full Text] [Related]
15. Can Beta-2-Adrenergic Pathway Be a New Target to Combat SARS-CoV-2 Hyperinflammatory Syndrome?-Lessons Learned From Cancer. Barbieri A; Robinson N; Palma G; Maurea N; Desiderio V; Botti G Front Immunol; 2020; 11():588724. PubMed ID: 33117402 [TBL] [Abstract][Full Text] [Related]
16. A critical evaluation of glucocorticoids in the management of severe COVID-19. Solinas C; Perra L; Aiello M; Migliori E; Petrosillo N Cytokine Growth Factor Rev; 2020 Aug; 54():8-23. PubMed ID: 32616381 [TBL] [Abstract][Full Text] [Related]
17. Should we unstress SARS-CoV-2 infected cells? Csukasi F; Rico G; Becerra J; Duran I Cytokine Growth Factor Rev; 2020 Aug; 54():3-5. PubMed ID: 32563554 [No Abstract] [Full Text] [Related]
18. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. van de Veerdonk FL; Netea MG; van Deuren M; van der Meer JW; de Mast Q; Brüggemann RJ; van der Hoeven H Elife; 2020 Apr; 9():. PubMed ID: 32338605 [TBL] [Abstract][Full Text] [Related]
19. Use of Nonsteroidal Anti-inflammatory Drugs for COVID-19 Infection: Adjunct Therapy? Zhao D; Zhang S; Igawa T; Frishman W Cardiol Rev; 2020; 28(6):303-307. PubMed ID: 33017365 [TBL] [Abstract][Full Text] [Related]
20. Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19. Robb CT; Goepp M; Rossi AG; Yao C Br J Pharmacol; 2020 Nov; 177(21):4899-4920. PubMed ID: 32700336 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]